Skip to main content

Market Overview

Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection

  • Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUSinitiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy for chronic HBV infection.
  • The companies announced a clinical collaboration agreement in August last year.
  • The 60-subject trial will evaluate the safety, pharmacokinetics, and antiviral activity of the triplet combination compared to the double combinations of VBR plus NrtI and AB-729 plus NrtI.
  • AB-729 is an RNA interference therapeutic targeted to hepatocytes. 
  • Vebicorvir is a capsid inhibitor.
  • Earlier today, Assembly Biosciences announced that it would not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as chronic suppressive therapy.
  • Price Action: ASMB shares are trading 5.9% lower at $5.2, while ABUS is down 0.8% at $3.8 in market trading hours on the last check Friday.

Related Articles (ASMB + ABUS)

View Comments and Join the Discussion!

Posted-In: Hepatits BBiotech News Penny Stocks Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at